The most important contribution of the systematic reviews by Matchar and colleagues and Kunz and associates is that they tell
us what we do not know, which is the adverse effects of long-term therapy with these agents. We need a large, long-term, 3-group,
randomized, controlled trial involving monotherapy and combination therapy with angiotensin-receptor blockers and angiotensin-converting
enzyme inhibitors. Until then, physicians should closely monitor patients with late-stage kidney disease who are using combination
therapy with these 2 drug classes.